Prime Medicine, Inc. files 8-K: a material agreement
A record notice: the source is linked, and no summary was written because none passed the fact check.
SEC filing
2 stories
A record notice: the source is linked, and no summary was written because none passed the fact check.
SEC filing
The gene-editing company priced a public offering as it reported dosing its first Wilson disease patient and cleared INDs for two liver programs.
SEC filing (4)